Guerci B, et al. - Via conducting this post hoc analysis of the DURATION-3 study, researchers determined factors associated with sustained glycemic response with exenatide once weekly (QW) or insulin glargine (IG) in patients with type 2 diabetes. In all, 61.5% of patients (n=467) completed 156 weeks of treatment. At Week 26, an HbA1c response was noted in 175 patients (61.0%; exenatide QW, n=95; IG, n=80). At Week 156, sustained response was observed in 84 of 175 responders (48.0%); there were more sustained responders with exenatide QW (22.7%) vs IG (13.9%). Three predictors of sustained response were (a) exenatide QW vs IG treatment, (b) lower HbA1c at Week 26, and (c) lower fasting serum glucose at Week 26.